Researchers from Abl Bio Inc. have published preclinical data for ABL-112, an Fc-competent bispecific antibody (BsAb) targeting TIGIT and 4-1BB (TIGIT x 4-1BB), being developed for the treatment of cancer.
Charcot-Marie-Tooth disease type 2E (CMT2E) is a slow and progressive neuropathy characterized by axonal dysfunction. Its clinical phenotype includes muscle weakness and atrophy, sensory loss and reduced nerve conduction velocity, among others.
CSPC Pharmaceutical Group Ltd. has obtained clearance from China’s National Medical Products Administration (NMPA) to conduct clinical trials with SYS-6040 for advanced solid tumors.
Marengo Therapeutics Inc. has entered into a multiyear research collaboration in oncology and autoimmune diseases with University of Pennsylvania Perelman School of Medicine. The research collaboration will provide deeper insights into the mechanism of action of Marengo’s selective dual T-cell agonists in oncology.
CEPI is partnering with Astrazeneca plc to advance VHH-based multispecific antibodies targeting influenza, while Harbour Biomed Ltd. has entered into a global strategic collaboration with Astrazeneca to discover and develop next-generation multispecific antibodies for immunology, oncology and other diseases.
Enigma Biomedical USA Inc. has selected two four-repeat tau (4R tau) protein PET imaging biomarkers to advance into phase I studies. These imaging biomarkers show promise as important new tools in advancing understanding of neurodegenerative diseases in which the misfolded 4R tau protein is implicated.
Mosaic variegated aneuploidy syndrome (MVAS) is an autosomal recessive disorder characterized by mosaic aneuploidy. Its clinical manifestations include growth and developmental delay, congenital malformations and increased cancer risk. Genetic variants involved in MVAS affect the chromosomal segregation during mitosis, where individuals often show mosaicism and chromosomal instability.
The first complete DNA methylation atlas of 39 human cell types reveals which genes can talk or are silenced, depending on whether their sequence is linked to methyl group epigenetic modification that regulates their expression. This map of on-and-off switches shows differences between the alleles inherited from the father and those from the mother, providing a view of gene expression that can be explored in health and disease independently of the information contained in the DNA sequence.
Axcynsis Therapeutics Pte Ltd. has described antibody-drug conjugates comprising an antibody or antigen-binding fragment targeting alkaline phosphatase placental type (ALPP) and/or alkaline phosphatase, germ cell type (ALPPL2) covalently linked to a cytotoxic agent through a linker reported to be useful for the treatment of cancer.
RSS
